Crinetics Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US22663K1079

SecurityCRNX / Crinetics Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership157,252 shares
Latest Disclosed Value $ 4,522,567
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 0.85% increase in ownership of CRNX / Crinetics Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 157,252 shares of Crinetics Pharmaceuticals, Inc. (US:CRNX) valued at $4,522,568 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 155,925 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 0.85% during the quarter. The current value of the position is $5,176,736 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Crinetics Pharmaceuticals EC US22663K1079 157,252 1,327 0.85 4,523 -13.52 0.1016
2025-05-28 2025-03-31 NP Crinetics Pharmaceuticals EC US22663K1079 155,925 8,060 5.45 5,230 -30.83 0.1254
2025-02-25 2024-12-31 NP Crinetics Pharmaceuticals EC US22663K1079 147,865 -5,276 -3.45 7,560 -3.39 0.1651
2024-11-26 2024-09-30 NP Crinetics Pharmaceuticals EC US22663K1079 153,141 27,890 22.27 7,826 39.51 0.1480
2024-08-26 2024-06-30 NP Crinetics Pharmaceuticals EC US22663K1079 125,251 10,215 8.88 5,610 4.18 0.1143
2024-05-28 2024-03-31 NP Crinetics Pharmaceuticals EC US22663K1079 115,036 -2,623 -2.23 5,385 28.62 0.1124
2024-02-26 2023-12-31 NP Crinetics Pharmaceuticals EC US22663K1079 117,659 8,085 7.38 4,186 28.48 0.0893
2023-11-28 2023-09-30 NP Crinetics Pharmaceuticals EC US22663K1079 109,574 17,557 19.08 3,259 96.50 0.0850
2023-08-25 2023-06-30 NP Crinetics Pharmaceuticals EC US22663K1079 92,017 8,991 10.83 1,658 24.38 0.0393
2023-05-26 2023-03-31 NP Crinetics Pharmaceuticals EC US22663K1079 83,026 0 0.00 1,333 -12.24 0.0355
2023-02-24 2022-12-31 NP Crinetics Pharmaceuticals EC US22663K1079 83,026 -446 -0.53 1,519 -7.32 0.0418
2022-11-25 2022-09-30 NP Crinetics Pharmaceuticals EC US22663K1079 83,472 1,858 2.28 1,639 7.69 0.0470
2022-08-25 2022-06-30 NP Crinetics Pharmaceuticals EC US22663K1079 81,614 10,460 14.70 1,522 -2.50 0.0420
2022-05-26 2022-03-31 NP Crinetics Pharmaceuticals EC US22663K1079 71,154 840 1.19 1,562 -21.83 0.0364
2022-02-25 2021-12-31 NP Crinetics Pharmaceuticals EC US22663K1079 70,314 15,476 28.22 1,998 73.05 0.0433
2021-11-24 2021-09-30 NP Crinetics Pharmaceuticals EC US22663K1079 54,838 0 0.00 1,154 11.71 0.0254
2021-08-26 2021-06-30 NP Crinetics Pharmaceuticals EC US22663K1079 54,838 12,071 28.23 1,034 58.19 0.0222
2021-05-27 2021-03-31 NP Crinetics Pharmaceuticals EC US22663K1079 42,767 -2,737 -6.01 653 1.71 0.0148
2021-02-25 2020-12-31 NP Crinetics Pharmaceuticals EC US22663K1079 45,504 0 0.00 642 -9.96 0.0165
2020-11-25 2020-09-30 NP Crinetics Pharmaceuticals EC US22663K1079 45,504 0 0.00 713 -10.54 0.0229
2020-08-27 2020-06-30 NP Crinetics Pharmaceuticals EC US22663K1079 45,504 27,003 145.95 797 194.10 0.0261
2020-06-01 2020-03-31 NP Crinetics Pharmaceuticals EC US22663K1079 18,501 1,748 10.43 272 -35.48 0.0111
2020-02-27 2019-12-31 NP Crinetics Pharmaceuticals EC 22663K107 16,753 0 0.00 420 67.33 0.0126
2019-11-27 2019-09-30 NP Crinetics Pharmaceuticals EC US22663K1079 16,753 16,753 252 0.0083
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.